Caris Molecular AI

About Caris Life Sciences

Founded in 2008, Caris Life Sciences has established itself as a pioneer in precision oncology, combining whole exome sequencing, whole transcriptome sequencing, and proteomic analysis with sophisticated AI algorithms. The company has processed over 1 million cases, performed 6.5+ million tests, and built a database of 740,000+ matched molecular and clinical outcomes records. Caris serves three key markets: patients seeking personalized treatment options, physicians requiring molecular blueprints for clinical decisions, and biopharma companies needing translational medicine and clinical development support. Their continuum of care spans disease detection, therapy selection, and treatment monitoring.

Therapeutic Areas